Tuberculosis (TB) is one of the world’s biggest global health crises. Killing 1.5 million people in 2020, TB is the world’s second deadliest infectious disease after COVID-19 (WHO).

Obsolete treatments, the lack of an effective vaccine, and the lack of suitable diagnostic tools make it difficult to control the global TB epidemic.

Some gains have been made in recent years; the first new TB drugs in half a century and the trial of a shorter course of treatment for drug-resistant TB (DR-TB). But the harsh reality remains - 10 million people fell sick with TB in 2020 and nearly half a million developed DR-TB, which is much harder to treat. Only about one-third of people with DR-TB accessed treatment in 2020. The majority go undiagnosed and therefore untreated.

IN 2021

Quick facts about Tuberculosis

EndTB clinical trials results
Drug-resistant Tuberculosis

TB Clinical trials: An unprecedented €34 million price tag in drug development

Press Release 26 Apr 2024
Doctors without Borders, MSF Scientific Days - Medical Research Day
Access to Healthcare

MSF Scientific Days 2024

Press Release 15 Apr 2024
Doctors Without Borders Southern Africa: Schools Health Programme Toolkit
Access to Healthcare

MSF School Health Program Implementation Toolkit

Toolkit 11 Mar 2024
A picture of the road leading to the village Vuma in Mbongolwane, KZN

Eshowe project closure – the power of partnerships

Press Release 5 Dec 2023
MSF, Doctors Without Borders, Democratic Republic of Congo, HIV/AIDS

SAMU-Supported Publications 2023

Article 4 Dec 2023
MSF,  endTB clinical trial results.

TB: Landmark Clinical Trial Redefines Multidrug-Resistant Tuberculosis Treatment Options

Press Release 15 Nov 2023